Advanced in Chronic Inflammatory Demyelinating Polyneuropathy

Dragana V. Lavrnic

6, Dr. Subotic Sr. Street, 11 000, 
Belgrade, SE, RS 
Advanced in Chronic Inflammatory Demyelinating Polyneuropathy
6, Dr. Subotic Sr. Street, 11 000, 
Belgrade, SE, RS 
OverviewLocationsClinical Research

Overview

Dragana Lavrnic practices in Belgrade, Serbia. Lavrnic is rated as an Advanced expert by MediFind in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. Their top areas of expertise are Myotonic Dystrophy Type 2, Myotonic Dystrophy, Paramyotonia Congenita, and Myasthenia Gravis.

Their clinical research consists of co-authoring 64 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles and participated in 2 clinical trials in the study of Chronic Inflammatory Demyelinating Polyneuropathy.

Locations

6, Dr. Subotic Sr. Street, 11 000, Belgrade, SE, Serbia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Biological
Study Drug: HYQVIA
Study Phase: Phase 3
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological
Study Drugs: HYQVIA, Intravenous Immunoglobulin G
Study Phase: Phase 3
View 1 Less Clinical Trial

64 Total Publications

Risk factors for generalization of ocular myasthenia gravis.
Risk factors for generalization of ocular myasthenia gravis.
Journal: Indian journal of ophthalmology
Published: March 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lavrnic's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile